Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

Chromosome 17q23 amplification occurs in ~11% of human breast cancers. Enriched in HER2+ breast cancers, the 17q23 amplification is significantly correlated with poor clinical outcomes. In addition to the previously identified oncogene WIP1, we uncover an oncogenic microRNA gene, MIR21, in a majorit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Nat Commun
Autors principals: Liu, Yunhua, Xu, Jiangsheng, Choi, Hyun Ho, Han, Cecil, Fang, Yuanzhang, Li, Yujing, Van der Jeught, Kevin, Xu, Hanchen, Zhang, Lu, Frieden, Michael, Wang, Lifei, Eyvani, Haniyeh, Sun, Yifan, Zhao, Gang, Zhang, Yuntian, Liu, Sheng, Wan, Jun, Huang, Cheng, Ji, Guang, Lu, Xiongbin, He, Xiaoming, Zhang, Xinna
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6226492/
https://ncbi.nlm.nih.gov/pubmed/30413718
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-07264-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars